ATE546527T1 - Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs - Google Patents

Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs

Info

Publication number
ATE546527T1
ATE546527T1 AT10003331T AT10003331T ATE546527T1 AT E546527 T1 ATE546527 T1 AT E546527T1 AT 10003331 T AT10003331 T AT 10003331T AT 10003331 T AT10003331 T AT 10003331T AT E546527 T1 ATE546527 T1 AT E546527T1
Authority
AT
Austria
Prior art keywords
cancer
liver cancer
dlk
detecting liver
antibody
Prior art date
Application number
AT10003331T
Other languages
English (en)
Inventor
Koji Nakamura
Hiroko Tanaka
Hiroyuki Yanai
Atsushi Miyajima
Original Assignee
Kanagawa Kagaku Gijutsu Akad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Kagaku Gijutsu Akad filed Critical Kanagawa Kagaku Gijutsu Akad
Application granted granted Critical
Publication of ATE546527T1 publication Critical patent/ATE546527T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT10003331T 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs ATE546527T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003399331 2003-11-28
JP2003401585 2003-12-01
JP2003423237 2003-12-19

Publications (1)

Publication Number Publication Date
ATE546527T1 true ATE546527T1 (de) 2012-03-15

Family

ID=34636972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10003331T ATE546527T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs
AT04819413T ATE466937T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04819413T ATE466937T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Country Status (8)

Country Link
US (2) US20080112956A1 (de)
EP (2) EP2204448B1 (de)
JP (1) JP4695982B2 (de)
AT (2) ATE546527T1 (de)
CA (1) CA2552553C (de)
DE (1) DE602004027085D1 (de)
ES (2) ES2382987T3 (de)
WO (1) WO2005052156A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056833A1 (en) 2006-11-10 2008-05-15 Livtech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
WO2009116670A1 (ja) 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
KR100964193B1 (ko) * 2009-04-17 2010-06-16 씨비에스바이오사이언스 주식회사 간암 예후 마커
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
EP2412792A1 (de) 2010-07-29 2012-02-01 The Procter & Gamble Company Flüssige Reinigungsmittelzusammensetzung
WO2012138100A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
CN102778566B (zh) * 2011-05-07 2016-01-13 上海市肿瘤研究所 Dlk1在肝癌诊断及预后判断中的应用
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
AU2013325443B2 (en) 2012-10-03 2019-01-31 Livtech, Inc. Anti-hDlk-1 antibody having an anti-tumor activity in vivo
RS58400B1 (sr) 2014-05-15 2019-04-30 Eisai R&D Man Co Ltd Jedinjenja pladienolid piridina i postupci primene
IL259198B2 (en) 2015-11-18 2023-04-01 Eisai R&D Man Co Ltd A solid form of paladinolide pyridine compound and methods of its use
CN110031629B (zh) * 2018-01-11 2020-08-18 上海交通大学 检测人血清dlk1蛋白的elisa试剂盒及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0673390T3 (da) * 1992-12-11 2000-11-13 Us Gov Health & Human Serv Deltalignende gen, som udtrykkes i neuroendokrine tumorer
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
JP4344231B2 (ja) * 2001-05-16 2009-10-14 財団法人神奈川科学技術アカデミー dlkを用いた未分化肝細胞の検出及び分離方法
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators

Also Published As

Publication number Publication date
ES2382987T3 (es) 2012-06-15
EP1702982A4 (de) 2007-04-25
JP4695982B2 (ja) 2011-06-08
EP2204448B1 (de) 2012-02-22
ES2345493T3 (es) 2010-09-24
EP2204448A1 (de) 2010-07-07
CA2552553A1 (en) 2005-06-09
JPWO2005052156A1 (ja) 2007-12-06
DE602004027085D1 (de) 2010-06-17
US20100151503A1 (en) 2010-06-17
US20080112956A1 (en) 2008-05-15
EP1702982B1 (de) 2010-05-05
ATE466937T1 (de) 2010-05-15
WO2005052156A1 (ja) 2005-06-09
EP1702982A1 (de) 2006-09-20
CA2552553C (en) 2015-01-06

Similar Documents

Publication Publication Date Title
JP6600302B2 (ja) 標的分子のマルチプレックス検出のための方法、キット、およびシステム、ならびにそれらの使用
ATE466937T1 (de) Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
CY1113686T1 (el) Συσκευη bio-αισθητηρα και οι μεθοδοι χρησης της
ATE436018T1 (de) Verbesserte immuntestverfahren
Früh et al. Strain field self-diagnostic poly (dimethylsiloxane) elastomers
DK2280083T3 (da) Nucleinsyreligand diagnostisk biochip
WO2008147382A8 (en) Integrated microfluidic assay devices and methods
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
ATE433108T1 (de) Radiomarkierungssatz und bindungstest
DE602007004666D1 (de) Verfahren zum analytennachweis unter verwendung von proximitätssonden
CY1115439T1 (el) Μεθοδοι και νουκλεϊκα οξεα για αναλυσεις διαταραχων του κυτταρικου πολλαπλασιασμου
ATE497602T1 (de) Hybride mikroauslegersensoren
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2019038706A3 (en) PAPER-BASED MOLECULAR DIAGNOSTIC DEVICE AND USES THEREOF
WO2008111464A1 (ja) スプライシング異常を指標とする抗ガン剤の作用検定方法
Dong et al. DNA walker-powered SERS logic aptasensors for accurate imaging and identification of tumor cells
WO2007105047A3 (en) Ultrasound molecular sensors and uses thereof
WO2007000320A3 (de) Verfahren zur diagnose von rheumatischen erkrankungen
ATE511636T1 (de) Verfahren zum nachweis biologischer organismen mittels raman-streuung
DE60329861D1 (de) Neue, auf der antigen-antikörper-reaktion beruhende sondenplatte sowie reagenzienkit und verfahren mit verwendung der sondenplatte
ATE529746T1 (de) Zusammensetzung und verfahren zum nachweis von analyten über eine polymerisierungsbasierte signalverstärkung
CY1113013T1 (el) Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
DE60139314D1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten